Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions
  • Sponsors Intra-Cellular Therapies

    • Most Recent Events

    • 25 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Nov 2014 Further results to be reported at the 7th Clinical Trials Conference on Alzheimer's Disease, according to an Intra-Cellular Therapies media release.
    • 14 Oct 2014 Results reported at the 139th Annual Meeting of the American Neurological Association, according to an Intra-Cellular Therapies media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top